Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone effectiveness and safety in schizophrenia
NCT03393026Phase 4Completed
- Sponsor
- Standard Chem & Pharm
- Start
- Jan 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lurasidone in schizophrenia, sponsored by Standard Chem & Pharm. Primary endpoint: Time to treatment failure at 6 weeks. Started Jan 2018; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03393026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393026.